Breaks Categories: News

WednesdayMar 11, 2026 9:50 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline

Oragenics (NYSE American: OGEN) announced it is exploring potential acquisitions of additional central nervous system assets focused on brain health and brain recovery indications that align with its proprietary intranasal drug delivery platform and lead candidate ONP-002. The company said the initiative complements its existing AI-enabled drug discovery collaboration with Receptor.AI and is intended to build a diversified CNS pipeline, while ONP-002 continues advancing through Phase IIa clinical trials in Australia targeting concussion and mild traumatic brain injury with plans for U.S. Phase IIb studies following a future IND submission. To view the full press release, visit https://ibn.fm/S8Srs About Oragenics,…

Continue Reading

WednesdayMar 11, 2026 9:40 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA Investment Conference As NV-387 Oral Gummies Drug Supply Completed

NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers. To view the full press release, visit https://ibn.fm/AILOV ABOUT…

Continue Reading

WednesdayMar 11, 2026 9:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline. To view the full press release, visit https://ibn.fm/MutVR About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage…

Continue Reading

TuesdayMar 10, 2026 10:39 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership will combine HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from three non-coplanar dimensions, with Mount Sinai’s clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring. By leveraging longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai’s clinical data resources, the collaboration aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical…

Continue Reading

TuesdayMar 10, 2026 9:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. To view the full…

Continue Reading

MondayMar 09, 2026 9:23 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Management to Participate in March 2026 Investor and Industry Conferences 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and…

Continue Reading

MondayMar 09, 2026 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network of clinics and builds on a nationwide partnership with neurocare AG to bring non-invasive neuroplastic therapies to patients. Peer-reviewed publications cited by the company report an 87% clinical response rate in treatment-resistant depression using short-term treatment protocols, while pilot programs incorporating hyperbaric oxygen therapy have…

Continue Reading

FridayMar 06, 2026 3:13 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline 

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move. “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology…

Continue Reading

FridayMar 06, 2026 9:18 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets 

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to…

Continue Reading

ThursdayMar 05, 2026 9:45 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective March 9, 2026

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced it will implement a 1-for-8 reverse stock split of its common stock effective at the opening of trading on March 9, 2026, while continuing to trade on the Nasdaq Capital Market under the symbol ADTX. The reverse split, approved by stockholders at a Feb. 13, 2026 special meeting and finalized by the company’s board of directors, is intended primarily to help the company regain compliance with Nasdaq’s minimum bid price requirement. To view the full press release, visit https://ibn.fm/jBJQ2 About Aditxt Aditxt, Inc. is a social innovation platform…

Continue Reading